Compare HubSpot Inc (HUBS) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Tempus AI — how do they compare? HubSpot Inc trades at $230.8 (market cap $10.98B), while Tempus AI trades at $70.5 (market cap $12.77B). The key difference: Tempus AI is the larger of the two by market cap, and Tempus AI is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Tempus AI for 22 Days on average.
| HUBS | TEM | |
|---|---|---|
Market Cap | $10.98B | $12.77B |
Volume | 1,027,893 | 8,980,490 |
Sector | Technology | Broad Market / Factor |
52-Week High | $494.58 | $99.28 |
52-Week Low | $170.39 | $41.55 |
Typical Hold Time | 78 Days | 22 Days |
Enterprise Value | $9.88B | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $231.84, up 6.86% in the past 24 hours, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $1.7B in 2022 to $3.1B in 2025, with net income turning positive in 2024. Recent analyst day highlighted AI strategy enhancements and margin expansion targets through 2030, while technical indicators show resistance near $232 with RSI suggesting potential overbought conditions.
HUBS presents a mixed outlook with strong fundamental growth offset by high valuation multiples (P/E 78.39) and technical resistance. The consensus price target of $243.65 offers modest upside, supported by 59.6% analyst buy ratings, but risks include competitive pressures in CRM software and execution challenges in AI integration. Cash flow growth and institutional accumulation provide support for long-term investors.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
